Track Evotec SE American Depositary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Evotec SE American Depositary Shares EVO Open Evotec SE American Depositary Shares in new tab

2.43 USD
EPS
-0.64
P/B
1.02
ROE
-24.06
Beta
1.30
Target Price
5.21 USD
Evotec SE American Depositary Shares logo

Evotec SE American Depositary Shares

🧾 Earnings Recap – Q3 2025

Evotec SE reported a 7% year-on-year decline in revenues for the first nine months of 2025, driven by challenges in the drug discovery market, although its Biologics segment demonstrated strong growth.

  • Group revenues were EUR 535.1 million, with a 12% decline in D&PD (Drug Discovery and Development) business, offset by 11% growth in Just-Evotec Biologics.
  • A transformative deal with Sandoz, worth over $650 million, underscores the potential of Evotec’s biologics division.
  • Cost-saving measures are expected to exceed EUR 110 million through 2025, aimed at enhancing operational efficiency amid market challenges.
  • Positive trends in customer proposals and improved change order performance signal stabilization in the D&PD segment.
  • Anticipation of up to four molecules entering Phase II clinical studies in 2026 highlights a strong pipeline and potential for future milestone payments.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 13, 2026
EPS-0.64
Book Value2.68
Price to Book1.02
Debt/Equity55.38
Growth
Revenue Growth-0.22%
Estimates
Forward P/E-14.36
Forward EPS-0.19
Target Mean Price5.21

DCF Valuation

Tweak assumptions to recompute fair value for Evotec SE American Depositary Shares (EVO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Evotec SE American Depositary Shares Logo Evotec SE American Depositary Shares Analysis (EVO)

Germany Health Care Official Website Stock

Is Evotec SE American Depositary Shares a good investment? Evotec SE American Depositary Shares (EVO) is currently trading at 2.43 USD. Market analysts have a consensus price target of 5.21 USD. This suggests a potential upside from current levels.

Earnings Schedule: Evotec SE American Depositary Shares is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is -0.19.

Investor FAQ

Does Evotec SE American Depositary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Evotec SE American Depositary Shares?

Evotec SE American Depositary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -0.64.

Company Profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Exchange Ticker
NMS (United States) EVO

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
May 5, 2008 1.900000
Oct. 20, 2021 4.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion